A disease-specific iPS cell resource for studying rare and intractable diseases.

"Declarations Ethics approval and consent to participateThis study was approved by the Ethics Committees of Kyoto University (G687), Tokushukai Shonan-Kamakura Hospital, and National Hospital Organization (NHO) (H26-NHO (shitei)-05) in Japan. Written informed consent was obtained from all patients or their guardians in accordance with the Declaration of Helsinki. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This work was supported by grants from the Core Center for iPS Cell Research of Research Center Network (JP21bm0104001 and 23bm1323001 to M.K.S. and S.Y.), Research on Intractable Diseases Using Disease-Specific iPSCs (16bm0609001h0005 to M.K.S. and S.Y.) for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED), the Program for Intractable Diseases Research utilizing Disease-specific iPSCs of AMED (JP21bm0804004 to M.K.S. and JP19bm0804001 to M.K.S. and S.Y.), and the iPS Cell Research Fund (to M.K.S.)."